首頁(yè)
瀏覽量: 214
- 產(chǎn)品名稱： Research Grade Mogamulizumab ( 莫格利組單抗 )
- 產(chǎn)品貨號(hào)： CSD00249
- 貨期： 現(xiàn)貨
- 價(jià)格與訂購(gòu)： 2480
- 數(shù)量：
庫(kù)存： 100
- 規(guī)格： 100μg
- 產(chǎn)品信息
- 如何訂購(gòu)
貨號(hào)（Catalog No.）
CSD00249
通用名INN
Mogamulizumab
純度(Purity)
>95%
濃度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
內(nèi)毒素(Endotoxin level)
Please contact with the lab for this information.
產(chǎn)品描述(Description)
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8.On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy 7.Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (?) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2.
別名(Alternative names)
AMG-761,KW-0761
靶點(diǎn);物種(Specificity target name;species)
CCR4/CD194[Homo sapiens]
種類(Species)
Humanized
受體鑒定(Receptor identification)
IgG1-kappa
CAS
1159266-37-1
存儲(chǔ)條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .
地 址：
產(chǎn)品銷售：
E - mail ：
郵 編：
Amily
